The authors found concurrent growth in pharmacy benefit manager market concentration and worsening of patient access measures across states from 2016 to 2025.
|Articles|March 17, 2010
Supplements and Featured Publications
- Implications of Early Treatment for Parkinson’s Disease [CME/CPE]
- Volume 16
- Issue 4
Posttest: Implications of Early Treatment for Parkinson's Disease
Advertisement
Instructions
After reading “Implications of Early Treatment for Parkinson’s Disease,” complete the program evaluation and select the 1 best answer to each of the following questions.
A statement of continuing education hours will be provided to those physicians and pharmacists who successfully complete and return the answer form and program evaluation and receive a passing grade of 70% or higher.
Articles in this issue
over 16 years ago
Participating Facultyover 16 years ago
Early Pharmacologic Treatment in Parkinson's DiseaseAdvertisement
Related to this article
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Durvalumab Plus EV Before Surgery in Cisplatin-Ineligible MIBC
2
ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's Costs
3
Payers, Eosinophil Thresholds Shape Who Gets a COPD Biologic
4
High FLT3-ITD Allelic Ratio Not Tied to Worse OS in AML in BIG-1 Data
5